NTRK2 and epilepsy: The disorders and pathological conditions induced or promoted by aberrant BDNF/TrkB signalling could be potentially treated by fine-tuned activation (e.g., stroke, neurodegenerative diseases) or suppression (e.g., epilepsy, cancer) of this pathway.